What is IDYA stock price today?

IDYA (Ideaya Biosciences Inc) stock is trading at $33.91 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IDYA stock going up or down today?

IDYA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IDYA stock now?

The decision to buy IDYA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IDYA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IDYA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IDYA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IDYA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IDYA's P/E ratio?

P/E ratio data for IDYA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IDYA's market cap?

IDYA (Ideaya Biosciences Inc) has a market capitalization of $2.85 billion, making it a small-cap stock.

What is IDYA's price to book ratio?

IDYA trades at a price-to-book (P/B) ratio of 2.76, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IDYA pay dividends?

IDYA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IDYA's dividend yield?

IDYA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IDYA stock a good long-term investment?

IDYA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IDYA's revenue growth rate?

IDYA has shown revenue growth of 0.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

IDYA is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in IDYA?

Key risks for IDYA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IDYA compare to its competitors?

Compare IDYA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IDYA's performance and positioning.

What is IDYA's stock price target for 2026?

Our AI model provides price targets for IDYA based on fundamental analysis: Bull case $44.08 (+30%), Base case $39.00 (+15%), Bear case $30.52 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IDYA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IDYA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IDYA's next earnings report?

IDYA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IDYA - Ideaya Biosciences Inc

NYSE * Health Care * Biotechnology

$33.91

+$1.40 (+4.31%)

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Key Statistics

Market Cap

$2.85B

P/B Ratio

2.76

EPS

$-1.28

Revenue Growth

+0.6%

Profit Margin

-0.5%

Employees

145

How IDYA Compares to Peers

IDYA has the fastest revenue growth among competitors

IDYA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IDYA(This stock)	$2.85B	N/A	1%	-0.5%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Ideaya Biosciences Inc Company Information

Headquarters: California; U.S.A
Website: www.ideayabio.com
Sector: Health Care
Industry: Biotechnology

IDYA - Ideaya Biosciences Inc

About Ideaya Biosciences Inc

IDYA Key Statistics

How IDYA Compares to Peers

Ideaya Biosciences Inc Company Information

IDYA Lician Score

IDYA Financial Snowflake

Upcoming Events for IDYA